Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Migraine

Free Subscription 31.10.2022 1 BMC Neurol 1 Brain 5 Headache

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Neurol

1. POZO-ROSICH P, Dodick DW, Ettrup A, Hirman J, et al
   Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.
   BMC Neurol. 2022;22:394.
   PubMed         Abstract available
   
   

   
   Brain

2. LACKOVIC J, Price TJ, Dussor G
   MNK1/2 contributes to periorbital hypersensitivity and hyperalgesic priming in preclinical migraine models.
   Brain. 2022 Oct 27. pii: 6775257. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Headache

3. YONKER ME, McVige J, Zeitlin L, Visser H, et al
   A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.
   Headache. 2022;62:1207-1217.
   PubMed         Abstract available
   
   
4. STERN JI, Chiang CC, Kissoon NR, Robertson CE, et al
   Narrative review of peripheral nerve blocks for the management of headache.
   Headache. 2022;62:1077-1092.
   PubMed         Abstract available
   
   
5. FISCHER-SCHULTE L, May A
   The 15-day threshold in the definition of chronic migraine is reasonable and sufficient-Five reasons for not changing the ICHD-3 definition.
   Headache. 2022;62:1231-1233.
   PubMed        
   
   
6. BELTRAMONE M, Redon S, Fernandes S, Ducros A, et al
   The teaching of headache medicine in France: A questionnaire-based study.
   Headache. 2022;62:1177-1186.
   PubMed         Abstract available
   
   
7. ORR SL, Shapiro RE
   The elephant in the room: How the underfunding of headache research stunts the field.
   Headache. 2022;62:1234-1238.
   PubMed        
   
   

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: